Supplementary Table 1.
Characteristics of Patients With COVID-19 With Hypertension in the ACEI/ARB and Non-ACEI/ARB Groups
| Characteristics | ACEI/ARB group (n = 31) | Non-ACEI/ARB group (n = 69) | P |
|---|---|---|---|
| Sex (male: female) | 14:17 | 37:32 | .285 |
| Age, median (IQR) | 67 (62–70) | 67.5 (57–71) | .479 |
| Duration, median (IQR) | 10(7–16.5) | 12 (8.8–16) | .041 |
| Respiratory symptoms, n (%) | 20 (64.5) | 48 (69.6) | .359 |
| Fever | 24 (77.4) | 53 (76.8) | .850 |
| Cough/expectoration | 15 (48.4) | 37 (53.6) | .528 |
| Shortness of breath | 5 (16.1) | 24 (34.8) | .047 |
| Chest distress | 3 (9.7) | 5 (7.2) | .710 |
| GI symptoms, n (%) | 4 (12.9) | 20 (29) | .082 |
| Diarrhea | 2 (6.5) | 10 (14.5) | .211 |
| Vomiting | 3 (9.7) | 8 (11.6) | .738 |
| Abdominal pain | 2 (2.9) | 2 (6.5) | .436 |
| Comorbidities on admission, n (%) | |||
| Diabetes | 8 (25.8) | 20 (29) | .616 |
| GI comorbidities | 6 (19.4) | 17 (24.6) | .513 |
| Chronic renal diseases | 4 (12.9) | 5 (7.2) | .398 |
| Coronary heart disease | 5 (16.1) | 13 (18.8) | .697 |
| COPD | 2 (6.5) | 7 (10.1) | .524 |
| Tumor | 1(3.2) | 4(5.8) | .566 |
| Laboratory examination on admission, median (IQR) | |||
| AST | 27.5 (24-30.75) | 31.5 (22-49) | .103 |
| ALT | 34 (20-48) | 32 (18-59.7) | .409 |
| TBIL | 11.6 (7.8-13.9) | 11.4 (7.4-17.1) | .153 |
| CRP | 23.97 (4-43) | 24 (6.7-62.5) | .406 |
| Lymphocyte | 1.16 (0.8-1.6) | 1.01 (0.73-1.3) | .109 |
| D-dimer | 0.76 (0.26-2.39) | 0.96 (0.58-2.1) | .609 |
| Severity, n (%) | .613 | ||
| Mild | 0 (0) | 2 (2.9) | |
| Moderate | 4 (12.9) | 7 (10.1) | |
| Severe | 24 (77.4) | 38 (55.1) | |
| Critical | 3 (9.7) | 22 (31.9) | |
| In-hospital management, n (%) | |||
| Antiviral drug | 19 (61.3) | 52 (75.4) | .093 |
| Antibiotic drug | 17 (54.8) | 40 (58) | .650 |
| Antifungal medications | 0 | 4 (5.8) | .077 |
| Systemic corticosteroids | 3 (9.7) | 26 (37.7) | .003 |
| Lipid-lowering drug | 8 (25.8) | 10 (14.5) | .196 |
| CCB | 15 (48.4) | 24 (34.8) | .237 |
| Beta-blocker | 10 (32.3) | 3 (4.3) | <.001 |
| Alpha-blocker | 1 (3.2) | 1 (1.4) | .573 |
| ACEI | 4 (12.9) | 0 | |
| ARB | 27 (87.1) | 0 | |
| Renal replacement therapy | 1 (3.2) | 5 (7.2) | .416 |
| Noninvasive ventilation | 0 | 5 (7.2) | .048 |
| Invasive ventilation | 2 (6.5) | 9 (13) | .287 |
NOTE. Bold values are time from onset to admission, days, median (IQR).
ALT, alanine aminotransferase; AST, aspartate transaminase; CCB, calcium channel blockers; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; IQR, Interquartile range; TBIL, total bilirubin.